- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
- Interventions
- Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
- Drug · Diagnostic Test · Genetic
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Kidney Transplant Rejection
- Interventions
- Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG (Intravenous Immunoglobulin )
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Ulcerative Colitis Acute
- Interventions
- Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product
- Drug
- Lead sponsor
- Berinstein, Jeffrey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
- Drug
- Lead sponsor
- DisperSol Technologies, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Miami, Florida • New Orleans, Louisiana • New York, New York + 2 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
- Interventions
- TAVT-45, Zytiga, Prednisone
- Drug
- Lead sponsor
- Tavanta Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Autoimmune Hepatitis
- Interventions
- LCP-Tacro (tacrolimus), Azathioprine
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab, Tazemetostat Pill, Capivasertib
- Drug
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
- Drug
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 17
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more
- Conditions
- Prostate Neoplasms
- Interventions
- Abiraterone acetate, Prednisone, Dextromethorphan hydrobromide, Theophylline
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • San Antonio, Texas
- Conditions
- Esophageal Stenosis
- Interventions
- prednisone, placebo
- Drug
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 48
- States / cities
- Orange, California • Palo Alto, California • Riverside, California + 41 more
- Conditions
- High-Risk Prostate Cancer
- Interventions
- Capivasertib, abiraterone acetate
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Prednisone
- Drug
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- 4 Years to 10 Years · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Phase I and Phase II: LAE001/prednisone + afuresertib
- Drug
- Lead sponsor
- Laekna Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
- Interventions
- Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, Low-fat meal
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Transplants and Implants
- Interventions
- Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 19 Years to 74 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania